16/01/2026
More than half of all cancer patients will need radiotherapy at some point during their treatment. Yet access to it remains one of the most uneven parts of global cancer care.
In many low- and middle-income countries, radiotherapy services are limited or unavailable. Some nations operate with less than 20% of the capacity they require, while others still have no machines at all. Even where equipment exists, shortages of trained specialists, long travel distances, and fragile health systems mean treatment is often delayed or never delivered.
The challenge goes beyond infrastructure alone. Time pressure, workforce constraints, and variability in clinical processes all play a role. When radiotherapy is delayed, cancers that could have been treated effectively can progress to stages that are far harder to manage.
At MVision AI, we are on a mission to help reduce these gaps in access.
AI will not replace clinicians or solve the global shortage of radiotherapy facilities. Used responsibly, however, it can help extend the reach of existing services by:
◆ Automating time-consuming tasks such as contouring
◆ Supporting more consistent treatment preparation
◆ Enabling remote collaboration and knowledge sharing
◆ Helping clinics manage higher patient volumes without compromising quality
We focus on building AI-powered solutions that fit into real radiotherapy workflows and address practical constraints faced by clinics. Workspace+ reflects this approach by combining contouring, synthetic imaging, dose prediction, and contour propagation in a single platform. By supporting more standardised and efficient preparation processes across teams, it supports clinics that are working under resource and workforce constraints.
Access to cancer treatment should not depend on where someone lives. The technology and clinical expertise already exist. What is needed now is collaboration between healthcare providers, policymakers, industry, and global health organisations to ensure that radiotherapy becomes more accessible, more consistent, and more resilient worldwide.
We are committed to contributing to that effort.
*Workspace+ is a CE-marked (CE 2797) medical device under EU MDR 2017/745; it is not available in all markets.
